Rehovot, Israel

Alex Veinberg


Average Co-Inventor Count = 7.1

ph-index = 15

Forward Citations = 495(Granted Patents)


Company Filing History:


Years Active: 1996-2005

Loading Chart...
15 patents (USPTO):Explore Patents

Title: **Innovative Contributions of Inventor Alex Veinberg**

Introduction

Alex Veinberg, a prolific inventor based in Rehovot, Israel, has made significant strides in the field of pharmaceuticals with a remarkable portfolio of 15 patents. His work primarily focuses on treatments for neurodegenerative diseases and related conditions, marking him as a pivotal figure in medical research and innovation.

Latest Patents

Among Veinberg's latest patents is the invention surrounding the use of the R-enantiomer of N-propargyl-1-aminoindan, which includes its salts and pharmaceutical compositions. This groundbreaking subject invention offers potential treatments for various afflictions such as Parkinson's disease, memory disorders, dementia, depression, and several neurodegenerative diseases. Additionally, methods for preventing nerve damage and preparing optically active derivatives of 1-aminoindan are detailed in the patent, showcasing a comprehensive approach to addressing complex medical challenges.

Career Highlights

Throughout his career, Alex Veinberg has been associated with esteemed organizations such as Teva Pharmaceutical Industries Limited and Technion Research & Development Foundation Limited. His contributions have not only enhanced therapeutic approaches but have also positioned him at the forefront of pharmaceutical innovation.

Collaborations

Veinberg has worked alongside notable colleagues Ruth Levy and John P. Finberg, sharing insights and expertise that have likely influenced his inventive processes. These collaborations highlight the importance of teamwork in advancing research and developing new solutions to health-related issues.

Conclusion

As a dedicated inventor, Alex Veinberg's work continues to inspire advancements in the pharmaceutical industry. His innovative contributions, exemplified through his latest patents and collaborations, underscore the potential for targeted therapies to improve patient outcomes in the realm of neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…